Cancer is a leading cause of morbidity and mortality worldwide, and the development of effective and targeted therapies is a major focus of current cancer research. There are a variety of modern approaches to the treatment of cancer, including chemotherapy, targeted therapies, immunotherapies, gene therapies, targeted radiotherapy, and targeted surgery.
Targeted cancer therapies are designed to specifically act on the molecular and cellular abnormalities that drive cancer growth and proliferation, and have the potential to offer improved efficacy and reduced side effects compared to traditional chemotherapy.
It is important to note that targeted therapies are typically used in combination with other cancer treatments, such as chemotherapy or radiation therapy, and the choice of therapy will depend on the specific type of cancer being treated.
Overall, modern anticancer approaches aim to specifically target the abnormalities that drive cancer growth and proliferation, and offer the potential for improved efficacy and reduced side effects compared to traditional chemotherapy.
This Special Issue will include the following topics:
• Precision medicine
• Targeted therapy, gene-editing therapies
• Immuno-oncology targets, monoclonal antibodies, small molecule inhibitors
• DNA damage response (DDR) targets
• Oncogenic kinases
• Autophagy targets
• Epigenetic targets
Dr. Milena Georgieva
Manuscripts should be submitted via our online editorial system at https://imr.propub.com by registering and logging in to this website. Once you are registered, click here to start your submission. Manuscripts can be submitted now or up until the deadline. All papers will go through peer-review process. Accepted papers will be published in the journal (as soon as accepted) and meanwhile listed together on the special issue website. Research articles, reviews as well as short communications are preferred. For planned papers, a title and short abstract (about 100 words) can be sent to the Editorial Office to announce on this website.
Submitted manuscripts should not have been published previously, nor be under consideration for publication elsewhere (except conference proceedings papers). All manuscripts will be thoroughly refereed through a double-blind peer-review process. Please visit the Instruction for Authors page before submitting a manuscript. The Article Processing Charge (APC) in this open access journal is 2500 USD. Submitted manuscripts should be well formatted in good English.
- Identification of Potential Inhibitors Targeting GTPase-Kirsten RAt Sarcoma Virus (K-Ras) Driven Cancers via E-Pharmacophore-Based Virtual Screening and Drug Repurposing ApproachUdhaya Kumar. S, Rinku Polachirakkal Varghese, V. Anu Preethi, C. George Priya Doss, Hatem ZayedFront. Biosci. (Landmark Ed) 2023, 28(11), 288; https://doi.org/10.31083/j.fbl281128814Downloads61Views
- LINC01572 is a Novel Prognostic Biomarker and Therapeutic Target in Lung AdenocarcinomaYaolin Zheng, Zhenshan Zhang, Xueyan Li, Leilei Wu, ... Dongping WeiFront. Biosci. (Landmark Ed) 2023, 28(10), 257; https://doi.org/10.31083/j.fbl281025729Downloads129Views
- Comparative Proteomic Analysis of Irradiation-Induced Radioresistant Breast Cancer Cells Using Label-Free QuantitationYingxia Ying, Lei Bian, Yiling Meng, Meichao Zhang, ... Dong LiFront. Biosci. (Landmark Ed) 2023, 28(10), 244; https://doi.org/10.31083/j.fbl281024425Downloads112Views